anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention comprises compounds of the general formula <FORM:0975921/C1/1> and their acid addition salts, wherein R1 represents a hydrogen or halogen atom, each of R2 and R3 represent a hydrogen atom and each of R4 and R5 represents an alkyl group containing 4 or less carbon atoms or R5 together with R2 or R3 or R4 represents an alkylene group containing at most 4 carbon atoms in a straight chain with the proviso that when a heterocyclic radical is attached to carbon atom 9 of the azathiaxanthene nucleus, it must contain 5 or 6-members, and the preparation thereof by reacting an organic metal compound of the formula <FORM:0975921/C1/2> wherein Hal represents a chlorine, bromine or iodine atom, with a 1-azathiaxanthone of the formula <FORM:0975921/C1/3> hydrolyzing the reaction product to form a 1-azathiaxanthydiol of the formula <FORM:0975921/C1/4> and treating this with a dehydrating agent, and, if desired, reacting the base with an organic or inorganic acid to produce the acid addition salt. The process of the invention may be combined with one for the preparation of the halo-1-azathiaxanthones by heating a halogenothiophenol with a solution of a diazonium salt of 3-aminopyridine-2-carboxylic acid in the presence of an alkali metal hydroxide, converting the alkali-metal salt of 2-carboxypyridyl-3-halogenophenyl sulphide resulting thereby to the free acid and then cyclising the corresponding acid halide in the presence of a cyclization agent. Separation of the compounds of the invention into the individual stereoisomers and separation of the halo-1-azathiaxanthones into the individual positional isomers are carried out by fractional crystallization. m-Dichlorodiphenyldisulphide is formed as a byproduct in the reaction between the diazonium salt and m-chlorothiophenol above. Pharmaceutical compositions comprise the compounds of the invention and an inert carrier. The compounds show marked histamine inhibition, seratonin inhibition, narcosis potentiation, adrenolytic, sedative, antipyretic or hypothermal effects according to the nature of the substituent groups therein.
The preemptive group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered within 60 minutes prior to incision. Each infusion will be administered over 15 minutes as recommended by manufacturer package insert.
Patients who are receiving ibrutinib as 1st or 2nd line treatment. After at least 12 months of ibrutinib, patients will be assessed for MRD. MRD-positive patients will be treated with ibrutinib + INVAC-1 for 6 months and at the end of the combined treatment period, MRD will be assessed. MRD-negative patients (defined as \<0.01% of CLL cells in total cells analyzed) will have the option to stop or continue ibrutinib. Then, they will be followed-up regularly for two years. Patients who become MRD-positive after being MRD-negative will resume ibrutinib single agent.
Increases in serum transaminases have been reported with use of rosuvastatin [see Adverse Reactions ( 6.1)]. In most cases, these changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after a brief interruption in therapy. In a pooled analysis of placebo-controlled trials, increases in serum transaminases to more than three times the ULN occurred in 1.1% of patients taking rosuvastatin versus 0.5% of patients treated with placebo. Marked persistent increases of hepatic transaminases have also occurred with rosuvastatin. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including rosuvastatin. 

Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury [see Use in Specific Populations ( 8.7)]. 

Consider liver enzyme testing before rosuvastatin initiation and when clinically indicated thereafter. Rosuvastatin is contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications ( 4)]. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue rosuvastatin.
The present disclosure provides an apparatus and system for remote health applications that are compliant with Health Insurance Portability and Accountability Act (HIPAA). The apparatus includes an adjustable stand to accommodate a digital communications device such as a tablet or smart phone. The dock is further operatively coupled to one or more sensors attached to a patient to monitor health parameters of the patient. A similar dock s provided with a medical care provider. The docks are registered, and as authentication, any exchange of information can occur only between registered docks. A simultaneous audio-video communication between the patient and the medical care provider and exchange medical and non-medical data that is governed by HIPAA can occur between the registered docks.
Methods and kits for producing cellular fractions enriched in adipose derived stem cells. Methods are provided where adipose tissue obtained from liposuction is enzymatically treated using a solution containing collagenase and divalent cations prior to the application of traditional methods of stromal-vascular fraction isolation. The enzymatic solutions may contain collagenase types I and II to a final concentration of about 0.001 mg/ml to 0.010 mg/ml. The divalent cations may be present as calcium, magnesium, and zinc chloride. The final concentration of calcium, magnesium, and zinc may range from about 0.001 to 0.1 micromolar; about 0.005 to 0.5 micromolar; and about 0.0015 to 0.15 micromolar, respectively. The enzymatic solutions may be generated using a kit where the collagenase and divalent components are held in separate containers until just prior to use. The cellular fractions isolated in this manner may be used in autologous fat grafts in therapeutic applications.
Patients with an odontogenic cervicofacial infection were treated with one dose of Solumedrol 125mg intravenous at time of surgery. Remainder of management was as per protocol.
Participants with FL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
A dry film coating composition for use in coating pharmaceuticals, food, confectionery forms, agricultural seeds, and the like, comprises a cellulosic polymer, and lactose. The composition may include an optional plasticizer, and an optional pigment. A method of coating substrates such as pharmaceutical tablets, food and confectionery forms, agricultural seeds, and the like comprises mixing a cellulosic polymer and lactose into water to form an aqueous coating suspension, spraying the coating suspension onto said substrates to form a film coating on said substrates, and drying the film coating on said substrates. Optionally, a plasticizer and/or pigment may be dispersed into the aqueous coating suspension. The method of making a dry film coating composition for use in coating pharmaceutical tablets, food and confectionery forms, agricultural seeds, and the like, comprises mixing a cellulosic polymer and lactose together to form a dry film coating composition. Optionally, a plasticizer and/or pigment is blended with the cellulosic polymer and lactose. A method of making a dry film coating composition for use in coating pharmaceutical tablets, food and confectionery forms, agricultural seeds, and the like comprises mixing a cellulosic polymer and lactose into water to form an aqueous coating suspension, and spray granulating the aqueous coating suspension to form a dry film coating compositions. Optionally, a plasticizer and/or pigment may be mixed into the aqueous coating suspension. An aqueous coating suspension for coating substrates such as pharmaceutical tablets, food and confectionery forms, agricultural seeds, and the like, comprises a mixture of a cellulosic polymer, lactose, water, and optionally, plasticizer and/or pigment.
INTRODUCTION: Osteoarticular pain is experienced by approximately 50% of patients with breast cancer under hormone therapy and can increase the risk of therapy discontinuation. Among complementary therapies, yoga has shown efficacy regarding reduction of fatigue, anxiety, pain due to hormone therapy and inflammation. Personalised patient education programmes increase engagement and motivation, and induce effective behavioural changes. The SKYPE programme, an integrated intervention combining physiotherapy, yoga and patient education, showed promising efficacy on hormone therapy-induced pain in a previous pilot study. In this study, we hypothesised that using theory-based patient education favour learning and practising 15 min of at-home yoga every day to decrease hormone therapy-induced pain.
METHODS AND ANALYSIS: This multicentre randomised study will assess the efficacy of the SKYPE programme on pain reduction compared with standard care in patients with breast cancer reporting osteoarticular pain due to hormone therapy. Main secondary objectives will describe pain evolution and characteristics, patient adhesion to yoga sessions and home practice, forward flexibility, quality of life, fatigue, anxiety and compliance to hormone therapy. Patients in the intervention group will participate in 1 weekly educational yoga session of 90 min for 6 weeks, supervised by physiotherapists (period 1). They will also perform daily at-home 15 min yoga sessions for 12 weeks, the total duration of the intervention (periods 1 and 2). Pain will be evaluated during physiotherapy check-ups at baseline (T0), at 6 weeks (T1) and at 12 weeks (T2).
ETHICS AND DISSEMINATION: This study was approved by the ethics committee (CPP Ile de France 8 on 22 June 2020). The results will be disseminated to patients and healthcare professionals, and published in a peer-reviewed journal.
TRIAL REGISTRATION NUMBER: NCT04457895.
Disease: Unresectable AJCC stage 3 or 4 melanoma. Nivolumab + Ipilimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
INTRODUCTION: Purulent flexor tenosynovitis (PFT) is a severe condition, and many patients report serious postoperative complications such as amputation, limited range of motion (ROM), or recurrence of symptoms. However, the ideal protocol for PFT treatment remains unknown owing to the limited number of studies. This retrospective cohort study aimed to identify prognostic factors for PFT treatment outcomes.
MATERIALS AND METHODS: Sixty-six patients (46 men and 20 women) with PFT who underwent surgical debridement at our hospital between September 2005 and January 2023 were included in this study. We conducted multivariate linear regression analysis with permanent deficit as the primary outcome. We defined the number of operations, laboratory data, interval from onset to debridement, previous conservative treatment, aetiology, Kanavel's signs, and medical history of diabetes mellitus as possible prognostic factors. We also defined the interval from onset to debridement as a secondary outcome and performed logistic regression analysis.
RESULTS: Overall, 25 (38%) patients had postoperative deficits. Longer interval from onset to surgery (odds ratio [OR]: 1.1, 95% confidence interval [CI]: 1.0-1.1) and polymicrobial infection (OR: 7.8, 95% CI: 1.56-38.8) were significant prognostic factors for unfavourable outcomes. Additional multivariate analysis showed that preoperative conservative treatment prolonged the interval to surgery (estimate, 16.4; standard error, 1.6; p < 0.05).
CONCLUSIONS: The results of this study suggest that indications for nonoperative treatment of PFT are limited and that earlier surgical debridement is recommended.
Rotavirus is infamous for being extremely contagious and for causing diarrhea and vomiting in infants. However, the symptomology is far more complex than what could be expected from a pathogen restricted to the boundaries of the small intestines. Other rotavirus sickness symptoms like fever, fatigue, sleepiness, stress, and loss of appetite have been clinically established for decades but remain poorly studied. A growing body of evidence in recent years has strengthened the idea that the evolutionarily preserved defensive responses that cause rotavirus sickness symptoms are more than just passive consequences of illness and rather likely to be coordinated events from the central nervous system (CNS), with the aim of maximizing the survival of the individual as well as the collective group. In this review, we discuss both established and plausible mechanisms of different rotavirus sickness symptoms as a series of CNS responses coordinated from the brain. We also consider the protective and the harmful nature of these events and highlight the need for further and deeper studies on rotavirus etiology.
FIELD: medicine, infections. SUBSTANCE: method involves vaccinations by simultaneous administration in body commercial vaccine preparations against indicated infectious diseases as a single human dose at the following combinations: a mixture of meningococcus A-vaccine and diphtheria anatoxin, a mixture of live smallpox vaccine and abdominal typhoid chemical sorbed vaccine at simultaneous administration of inactivated chromatography influenza vaccine or normal human immunoglobulin. Method ensures to carry out vaccine prophylaxis for the short time at minimal cost. Method provides the specific body protection against infection by pathogens of meningococcus infection, diphtheria, abdominal typhoid, natural smallpox, influenza and viral hepatitis. EFFECT: retained effectiveness of prophylaxis. 6 tbl
PRP is injected using 22 gauge needles through the classic approach (lateral midpatellar) in a sterile setting. The PRP is obtained from a maximum 16 cc sample of the patients' blood drawn at the time of treatment. Using sterile technique, the venous blood is transferred to a centrifuge and prepared by the centrifugation process for 5 minutes. 4-7 mL of PRP is transferred from the large outer syringe into the small inner syringe and injected within 30 minutes of being spun to negate the need of anticoagulants. The procedure will take approximately 20-30 minutes.
PURPOSE: To avert the danger of starch dust and explosion and contamination with bacteria accompanying a starch molding operation by using a porous polymer as a substitute for the starch to be used for the conventional starch molds in production of products exclusive of cast food or food. CONSTITUTION: Molten or fluid product stock is poured into the molds consisting of the porous polymers. The fluid product stock is then gelatinized or solidified and moisture is absorbed into the porous polymers during this time. Molded goods are then taken out. The fluid product stock usually contg. about 5 to 85% moisture or solvent is used. The products are used for materials for confectionery, drugs, cosmetics, etc. The porous polymer are hydrophilic and have an average pore size of preferably 0.8 to 2000μm. Such polymers include, for example, high-density polyethylene, polypropylene, polytetrafluoroethylene, ethylene-vinyl acetate copolymer, etc.
Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; total volume 0.24 mL per side, i.e. 4 x 0.06 mL placebo solution; mode of administration: intramuscular injection.
OBJECTIVE: To study the relationship of serum markers of glial and neuronal degeneration with neuropsychological tests reflecting various cognitive domains of executive functions in patients with alcohol use disorders (AUDs).
MATERIAL AND METHODS: A total of 74 men participated in the study, including 30 healthy volunteers and 44 patients with AUDs. The study of executive functioning was carried out using Go/No-Go, Corsi and Color Stroop tests. Concentrations of calcium-binding protein (S100B), myelin basic protein (MBP) and glial fibrillar acid protein (GFAP) «Sandwich» were determined in the blood serum of patients and control groups by solid-phase enzyme immunoassay.
RESULTS: The levels of S100B and MBP in patients with AUDs were significantly higher than the control values (U=194.5; p=0.002 and U=198.5; p=0.003), whereas the content of GFAP in patients did not significantly exceed the control values (U=287; p=0.181). Patients with AUDs performed worse on the Go/No-Go task (U=133; p=0.002), the Corsi test (U=133.5; p=0.003) and the Color Stroop test (U=60; p<0.001) compared to controls. Significant Spearman's correlations were found between the concentration of S100B and the number of errors in the Go/No-Go task (R=0.537; p=0.004), as well as the duration of alcohol dependence (R=0.321; p=0.021). The MBP content in blood serum was directly correlated with the number of errors in the Go/No-Go task (R=0.654; p<0.001) and inversely with spatial working memory in the Corsi test (R=-0.588; p<0.001).
CONCLUSION: The serum levels of S100B and MBP correlate with various domains of executive functions (inhibitory control and spatial working memory) in patients with AUDs. It is assumed that these biomarkers can potentially be used as markers of progression, tracking subtle cognitive changes among patients with AUDs.
<P>PROBLEM TO BE SOLVED: To obtain a cosmetic composition containing a Panax ginseng C.A. Meyer extract, which suppresses the occurrence of dandruff of the hair to mitigate itching, is excellent simultaneously in hair state, feeling in use, controllability-improving efficacy, skin disease improvement, skin softening, and skin moisturizing efficacy, and has transparent appearance and safeness; and a cosmetic which maintains transparent appearance and safeness despite the deposition of Panax ginseng C.A. Meyer.  <P>SOLUTION: This cosmetic composition contains, as its effective component, an extract mixture consisting of an extract of Panax ginseng C.A. Meyer and at least two extracts selected from extracts of Artemisia capillaris Thunb, Schizonepeta tenuifolia Briquet, and Foeniculum vulgare Mill; otherwise, the composition contains the Panax ginseng C.A. Meyer extract, an amine oxide, a cationic surfactant, and a water-soluble silicone polyether. The transparent cosmetic is composed of the cosmetic composition and Panax ginseng C.A. Meyer precipitated and contained therein.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
OBJECTIVE: The purpose of this study was to evaluate the effectiveness of the drugs Solifenacin and Vesusten in relation to the treatment of neurogenic bladder overactivity in multiple sclerosis (MS).
MATERIALS AND METHODS: A prospective, single-site, single-center, placebo-controlled, parallel-group, comparative clinical trial was conducted. The study included 41 MS patients of both sexes aged 18-50 years with urodynamically confirmed detrusor overactivity. Data were obtained by completing a voiding diary. Clinical data were assessed before taking the drugs, during a monthly course of therapy and after a month of observation after the end of treatment. The results were processed by nonparametric methods of statistical analysis.
RESULTS: Both drugs are effective in patients with MS to correct neurogenic bladder overactivity. At the same time, in comparison with Solifenacin, Vesusten showed better clinical efficacy in relation to clinical manifestations of overactive bladder (OAB). Pollakiuria and urgency also decreased significantly. The best profile of maintaining the therapeutic effect was observed with Vesusten in relation to the frequency of urinary incontinence and OAB syndrome. The results of the study established that Solifenacin and Vesusten can cause adverse events, the frequency and nature of which correspond to the data declared by the manufacturers.
DISCUSSION: Considering the clinical features of MS, the priority in treatment, in addition to effectiveness, is maximum conservative therapy. The currently recommended therapy for neurogenic bladder overactivity is limited to the use of M-anticholinergics and intradetrusor administration of botulinum toxin type A drugs. At the same time, multiple side effects of such treatment are observed with a high frequency. The emergence of a new effective therapeutic agent is a promising direction for the treatment of neurogenic bladder overactivity in patients with MS.
CONCLUSIONS: Both Solifenacin and Vesusten are effective therapeutic options for the management of neurogenic bladder overactivity in MS. However, Vesusten has a more significant therapeutic profile, expressed in the correction of pollakiuria, urge incontinence and urgency. After completion of therapy, Vesusten, in comparison with Solifenacin, demonstrates the retention of a strong therapeutic effect. Based on the combination of various assessment parameters of a voiding diary, Vesusten is a priority therapeutic agent that determines the best quality of life profile for patients with MS.
FIELD: pharmaceuticals; cosmetic industry.SUBSTANCE: group of inventions relates to the pharmaceutical and cosmetic industry, namely to the extract ofMimosa pudicacells with a mimosine content of less than 5 ng/g of dry weight and its application. A method for obtainingin vitroextract ofMimosa pudicacells with a mimosine content of less than 5 ng/g of dry weight, including the following steps: а. providing sterile plant materialMimosa pudica, b. dedifferentiation of cells from the specified plant material, с. suspension of culture of undifferentiated cells in a liquid medium to maintain them in an undifferentiated state, d. growing a biomass culture of undifferentiated cells in a culture medium, i.e. stopping the cultivation and obtaining a cell extract with a mimosine content of less than 5 ng/g of dry weight, while the culture medium of Stage c) and/or Stage d) contains a phenylammonium-lyase substrate selected from the group, consisting of phenylalanine, in particular L-phenylalanine, cinnamic acid, aspartic acid, glutamic acid and their mixtures.In vitroextract ofMimosa pudicacell culture with inhibitory activity against thymic stromal lymphopoietin. Composition with inhibitory activity against thymic stromal lymphopoietin. Dermatological composition for the treatment of inflammatory skin disease selected from atopic dermatitis, itching and pruritic condition due to itching, eczema and psoriasis. Application of the extract for cosmetic treatment of skin aging and skin diseases associated with oxidative stress of the skin, including oxidative stress due to environmental pollution. A cosmetic composition for cosmetic treatment selected from the treatment of skin aging and skin diseases associated with oxidative stress of the skin.EFFECT: above extract is characterized by a mimosin content of less than 5 ng/g dry weight and is effective for inhibiting thymic stromal lymphopoietin; for treating inflammatory skin disease selected from atopic dermatitis, itching and pruritic condition due to itching, eczema and psoriasis; for treating skin aging and skin diseases associated with oxidative stress of the skin, including oxidative stress due to environmental pollution.26 cl, 4 dwg, 2 tbl, 4 ex
This group will receive the Zafirlukast pre-treatment nasally (400 mcg in 150 mcl in each nostril) once before the allergen challenge (0.87mcg Fel d1 in 100mcl in each nostril) in the first study visit. In the second study visit, they will receive a placebo pre-treatment nasally (150 mcl each nostril) once before the allergen challenge (0.87mcg Fel d1 in 100mcl in each nostril).
Phase I involves developing a final design for an adjustable, immediate fit prosthesis. We will recruit 5-10 participants age 3-12 to complete in-lab testing and evaluation of several designs. This testing will lead to the final product design to be tested in Phase II.